Table 1 Pharmacokinetic parameters of... | American Society of Hematology

Table 1

Pharmacokinetic parameters of continuously IV-infused blinatumomab in the first treatment cycle of MRD⁺ ALL patients

	AUC_0-28, d × pg/mL	AUC_0-inf, d × pg/mL	Css, pg/mL	T_{1/2, β}, h	CL, L/d/m²	V_Z, L/m²
Mean ± SD	19 659 ± 4413	19 764 ±4474	731 ± 163	1.250 ± 0.634	22.3 ± 5.0	1.61 ±0.74
Range	12 864-27 979	12 914-28 135	492-1050	0.52-2.76	15.2-32.5	0.87-3.27

	AUC_0-28, d × pg/mL	AUC_0-inf, d × pg/mL	Css, pg/mL	T_{1/2, β}, h	CL, L/d/m²	V_Z, L/m²
Mean ± SD	19 659 ± 4413	19 764 ±4474	731 ± 163	1.250 ± 0.634	22.3 ± 5.0	1.61 ±0.74
Range	12 864-27 979	12 914-28 135	492-1050	0.52-2.76	15.2-32.5	0.87-3.27

MRD indicates minimal residual disease; AUC, area under the curve; Css, steady-state serum concentration; T_1/2,β, elimination serum half-life; CL, systemic clearance; and V_Z, distribution volume.

View Large

This Feature Is Available To Subscribers Only